Sensei Biotherapeutics, after recent layoffs and potential wind-down, merged with Faeth Therapeutics and adopted Faeth's Phase 2 cancer drug as its new lead program.
Longevity News
Only a couple of months ago, Sensei Biotherapeutics was laying off staff and mulling winding down the company.
Source: FierceBiotech - All • Published: 18 Feb 2026, 15:47
Continue exploring
Related longevity signals
Fight Aging!Bacterial Lipoic Acid Protein Ligase A Improves Mammalian Mitochondrial Function and HealthThis article previews research on using a bacterial enzyme to boost mitochondrial protein modification and overall cellular energy, framed as a potential metabolic-enhancing therapy. It invites readers curious about cross-species gene therapy approaches aimed at improving healthspan and age-related function.Nature - BiotechnologySEQURNA enhances FLASH-seq gene detection while eliminating DTT dependenceSEQURNA-focused methods article presenting a comparative benchmark of a synthetic thermostable RNase inhibitor for improved single-cell, full-length RNA-seq workflows.Longevity TechnologyClaremedica’s digital test finds 90% of new dementia cases earlyA report on a primary care group’s adoption of a digital cognitive assessment and what readers will learn about its implementation and uptake.Longevity TechnologyRetro Biosciences expands early trial for drug targeting Alzheimer’s, Parkinson’sA short news article about an early-stage clinical trial expansion testing higher doses of a candidate neurodegenerative drug, outlining safety and dosing goals and what readers can expect to learn.